The acquisition will expand the diagnostics and biopharma portfolio, leveraging Personalis' MRD leadership and data assets. The deal is structured as a stock transaction with an option for partial cash, aiming for strong growth, improved margins, and positive cash flow by 2027.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.